WO2023037173 - A PHARMACEUTICAL MICRONUTRIENT COMPOSITION FOR USE TO SIMULTANEOUSLY IMPROVE NERVOUS SYSTEM FUNCTION, COGNITIVE ABILITY AND RESPONSE TO STRESSORS
National phase entry:
Publication Number
WO/2023/037173
Publication Date
16.03.2023
International Application No.
PCT/IB2022/056411
International Filing Date
12.07.2022
Title **
[English]
A PHARMACEUTICAL MICRONUTRIENT COMPOSITION FOR USE TO SIMULTANEOUSLY IMPROVE NERVOUS SYSTEM FUNCTION, COGNITIVE ABILITY AND RESPONSE TO STRESSORS
[French]
COMPOSITION PHARMACEUTIQUE DE MICRONUTRIMENTS À UTILISER POUR AMÉLIORER SIMULTANÉMENT LA FONCTION DU SYSTÈME NERVEUX, LA CAPACITÉ COGNITIVE ET LA RÉPONSE À DES FACTEURS DE STRESS
Applicants **
RATH, Matthias W
2320 French Alps Avenue
Henderson, NV 89044, US
Inventors
NIEDZWIECKI, Aleksandra
2320 French Alps Avenue
Henderson, Nevada 89044, US
GOC, Anna
750 North King Road, apt. # 1102
San Jose, California 95133, US
BOULIKAS, Parthena
750 North King Road, apt # 1102
San Jose, California 95133, US
Priority Data
17/373,335
12.07.2021
US
17/549,086
13.12.2021
US
17/552,189
15.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1223 | |
| EPO | Filing, Examination | 3833 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 639 | |
| USA | Filing, Examination | 2710 |
Total: 8995 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Micronutrient compositions, comprising NAD+ in the range of 0.1 mg to 20,000 mg, American Ginseng in the range of 1 mg to 50,000 mg, and Pyrroloquinone quinone in the range of 0.1 mg to 50,000 mg improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12,10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.[French]
Compositions de micronutriments comprenant du NAD+ dans la plage de 0,1 mg à 20 000 mg, du ginseng américain dans la plage de 1 mg à 50 000 mg et de la pyrroloquinoline-quinone dans la plage de 0,1 mg à 50 000 mg pour améliorer la santé cérébrale et les fonctions du système nerveux. Diverses combinaisons de formules ont été utilisées. Les formules 12, 10 et 5 présentent de multiples effets positifs simultanés dans le support de fonctions clés dans les cellules constituant notre système nerveux essentielles pour une santé mentale optimale, y compris la protection de cellules du système nerveux contre divers facteurs nocifs, l'augmentation de la production d'ATP, la stimulation de la biogenèse des mitochondries, l'augmentation du potentiel de la membrane mitochondriale, l'augmentation des fonctions mitochondriales (activité complexe I), présentant une capacité anti-inflammatoire et une sécrétion de BDNF accrue.